Clinical cancer research, 2018-10, Vol.25 (2), p.478-486
- Laubach, Jacob P.
- Liu, Chia-Jen
- Raje, Noopur S.
- Yee, Andrew J.
- Armand, Philippe
- Schlossman, Robert L.
- Rosenblatt, Jacalyn
- Hedlund, Jacquelyn
- Martin, Michael
- Reynolds, Craig
- Shain, Kenneth H.
- Zackon, Ira
- Stampleman, Laura
- Henrick, Patrick
- Rivotto, Bradley
- Hornburg, Kalvis T.V.
- Dumke, Henry J.
- Chuma, Stacey
- Savell, Alexandra
- Handisides, Damian R.
- Kroll, Stew
- Anderson, Kenneth C.
- Richardson, Paul G.
- Ghobrial, Irene M.
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Laubach, Jacob P.
- Liu, Chia-Jen
- Raje, Noopur S.
- Yee, Andrew J.
- Armand, Philippe
- Schlossman, Robert L.
- Rosenblatt, Jacalyn
- Hedlund, Jacquelyn
- Martin, Michael
- Reynolds, Craig
- Shain, Kenneth H.
- Zackon, Ira
- Stampleman, Laura
- Henrick, Patrick
- Rivotto, Bradley
- Hornburg, Kalvis T.V.
- Dumke, Henry J.
- Chuma, Stacey
- Savell, Alexandra
- Handisides, Damian R.
- Kroll, Stew
- Anderson, Kenneth C.
- Richardson, Paul G.
- Ghobrial, Irene M.
- Titel
- A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
- Ist Teil von
- Clinical cancer research, 2018-10, Vol.25 (2), p.478-486
- Erscheinungsjahr
- 2018
- Quelle
- EZB Electronic Journals Library
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1078-0432DOI: 10.1158/1078-0432.CCR-18-1325Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6335171
- Format
- –